Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics
GET POWR RATINGS... FREE!
FULC POWR Grades
- FULC scores best on the Sentiment dimension, with a Sentiment rank ahead of 71.15% of US stocks.
- FULC's strongest trending metric is Stability; it's been moving up over the last 179 days.
- FULC's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).
FULC Stock Summary
- The ratio of debt to operating expenses for Fulcrum Therapeutics Inc is higher than it is for about merely 0.5% of US stocks.
- With a price/sales ratio of 45.61, Fulcrum Therapeutics Inc has a higher such ratio than 95.88% of stocks in our set.
- As for revenue growth, note that FULC's revenue has grown 117.19% over the past 12 months; that beats the revenue growth of 93.01% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Fulcrum Therapeutics Inc, a group of peers worth examining would be CGEN, SURF, PRQR, CDAK, and FUSN.
- Visit FULC's SEC page to see the company's official filings. To visit the company's web site, go to www.fulcrumtx.com.
FULC Valuation Summary
- In comparison to the median Healthcare stock, FULC's price/earnings ratio is 136.16% lower, now standing at -13.2.
- FULC's EV/EBIT ratio has moved down 5.1 over the prior 26 months.
- FULC's price/earnings ratio has moved down 5.2 over the prior 26 months.
Below are key valuation metrics over time for FULC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FULC | 2021-08-31 | 63.7 | 8.8 | -13.2 | -12.5 |
| FULC | 2021-08-30 | 59.0 | 8.1 | -12.3 | -11.5 |
| FULC | 2021-08-27 | 58.2 | 8.0 | -12.1 | -11.3 |
| FULC | 2021-08-26 | 56.7 | 7.8 | -11.8 | -11.0 |
| FULC | 2021-08-25 | 58.3 | 8.0 | -12.1 | -11.3 |
| FULC | 2021-08-24 | 56.4 | 7.8 | -11.7 | -10.9 |
FULC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- FULC has a Quality Grade of D, ranking ahead of 14.4% of graded US stocks.
- FULC's asset turnover comes in at 0.108 -- ranking 260th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows FULC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.108 | 1 | -1.792 |
| 2021-03-31 | 0.090 | 1 | -1.731 |
| 2020-12-31 | 0.069 | 1 | -1.552 |
| 2020-09-30 | 0.037 | 1 | -2.003 |
| 2020-06-30 | 0.024 | 1 | -2.355 |
| 2020-03-31 | 0.008 | 1 | -3.830 |
FULC Price Target
For more insight on analysts targets of FULC, see our FULC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $34.86 | Average Broker Recommendation | 1.5 (Moderate Buy) |
FULC Stock Price Chart Interactive Chart >
FULC Price/Volume Stats
| Current price | $8.36 | 52-week high | $33.10 |
| Prev. close | $8.34 | 52-week low | $6.85 |
| Day low | $7.97 | Volume | 739,624 |
| Day high | $8.55 | Avg. volume | 601,916 |
| 50-day MA | $14.12 | Dividend yield | N/A |
| 200-day MA | $17.88 | Market Cap | 341.49M |
Fulcrum Therapeutics, Inc. (FULC) Company Bio
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Latest FULC News From Around the Web
Below are the latest news stories about Fulcrum Therapeutics Inc that investors may wish to consider to help them evaluate FULC as an investment opportunity.
Vericel Corporation (VCEL) Q4 Earnings Miss EstimatesVericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ETCAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2021 financial results will be released on Thursday, March 3, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on rec |
These 2 Stocks Could Be Bought Out, Says Credit SuisseThe economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth a total of $2.5 trillion, more than 25% higher than the previous record, 2015’s $1.96 trillion. |
2 ‘Strong Buy’ Stocks That Could Be Bought Out, According to Credit SuisseThe economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth |
Multiple insiders bought Fulcrum Therapeutics, Inc. (NASDAQ:FULC) stock earlier this year, a positive sign for shareholdersGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
FULC Price Returns
| 1-mo | -23.86% |
| 3-mo | -16.06% |
| 6-mo | N/A |
| 1-year | -9.82% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.74% |
| 2021 | 51.07% |
| 2020 | -29.63% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...